CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
<< View More Conferences
2018 World Congress on GI Cancer
Oncology Conference Multimedia
View more videos >>
Dr. O'Reilly on Immunotherapy in Pancreatic Cancer
Dr. Finn Recaps Second-Line Advancements in HCC
Dr. Demetri on Larotrectinib in TRK-Fusion GI Cancers
Oncology Conference Articles
Regorafenib Dose-Escalation Superior to Standard Dosing in mCRC
Results from the regorafenib dose optimization study (ReDOS) presented at the 2018 World Congress on GI Cancer established that the strategy of escalating regorafenib from 80 mg to 160 mg per day was superior to starting at a dose of 160 mg per day.
TAS-102 Benefit Consistent in Real-World Study for mCRC
TAS-102 (trifluridine/tipiracil; Lonsurf) continued to show consistent benefits and safety in a real-world treatment setting for patients with refractory metastatic colorectal cancer.
O'Reilly Discusses Status of Immunotherapy Research in Pancreas Cancer
Eileen M. O’Reilly, MD, speaks to the progress being made with immune therapies in pancreatic cancer.
Atezolizumab Combo Not Superior to Regorafenib for mCRC
Atezolizumab alone or in combination with cobimetinib failed to show superior overall survival compared with regorafenib for patients with chemorefractory metastatic colorectal cancer.
TAS-102 Prolongs Survival in Phase III Gastric Cancer Study
TAS-102 (trifluridine/tipiracil; Lonsurf) provided a 31% reduction in the risk of death compared with placebo in patients with heavily pretreated metastatic or advanced gastric cancer.
Pembrolizumab Fails to Show Survival Benefit in PD-L1 ≥1 Gastric/GEJ Cancers
Second-line treatment with pembrolizumab (Keytruda) did not significantly improve overall survival or progression-free survival in patients with advanced or metastatic gastric or gastroesophageal junction cancer with a PD-L1 combined positive score ≥1.
Conroy Highlights Practice-Changing Findings With Chemo Combo in Pancreatic Cancer
Thierry Conroy, MD, discusses the PRODIGE 24/CCTG PA.6 trial and shares his insight on future research with this treatment regimen.
TAS-120 Shows Promise in Cholangiocarcinoma
TAS-120 demonstrated a clinically meaningful benefit with a manageable toxicity profile in patients with cholangiocarcinoma harboring
gene fusions, including patients who had progressed on an FGFR inhibitor.
Adding SIRT Does Not Provide Survival Benefit in Advanced HCC, Except in Select Patients
Selective internal radiation therapy in combination with sorafenib (Nexavar) did not provide a significant survival improvement compared with sorafenib alone in patients with advanced hepatocellular carcinoma.
Ramucirumab Extends Survival for AFP-Elevated HCC in Pooled Analysis
Treatment with second-line ramucirumab improved median overall survival by 3.1 months compared with placebo in patients with advanced hepatocellular carcinoma with alpha-fetoprotein levels ≥400 ng/ml.
Overcoming Challenges in the Management of mCRC
Novel Agents Spark New Approaches for Triple-Negative Breast Cancer
FDA Grants Pembrolizumab/Axitinib Combo Priority Review for Frontline RCC
FDA Grants Avelumab/Axitinib Combo Priority Review for RCC
Hereditary Prostate Cancer—What Urologists Should Know
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.